- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02943382
Fingerprick Autologous Blood (FAB) in Mebomian Gland Dysfunction (MGD)
The Use of Fingerprick Autologous Blood (FAB) in the Treatment of Mebomian Gland Dysfunction (MGD)
Dry eye disease remains one of the most common complaints seen in ophthalmic clinics. Causes of dry eye are multifactorial, with the most common cause of evaporative dry eye disease being meibomian gland dysfunction (MGD).
Fingerprick autologous blood (FAB) is a novel method which uses a patient's own blood to treat dry eye conditions.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Dry eye disease remains one of the most common complaints seen in ophthalmic clinics, with one in four patients reporting symptoms of the condition (including soreness, foreign body sensation or temporary blurring of vision). Causes of dry eye are multifactorial, with the most common cause of evaporative dry eye disease being meibomian gland dysfunction (MGD).
A chronic, abnormality of the glands lining the eyelid. MGD results in alteration of the tear film, symptoms of eye irritation, inflammation and ocular surface disease. In those with moderate or severe disease (as defined by symptoms, clinical signs and corneal staining), anti-inflammatory therapy is recommended, with topical steroids or oral tetracyclines. However, both these treatments are accompanied by side effects; topical steroids cause increased intraocular pressure, and predispose to eye infection and cataracts, whilst tetracyclines cause skin phototoxicity.
Autologous serum drops are used as a treatment for severe dry eyes by providing growth factors and anti-inflammatory mediators to the ocular surface. It is derived from the liquid component of blood, after clotting factors and blood cells have been extracted. Obtaining this carries its own problems: numerous venesections from the patient, fridge storage to prevent bacterial contamination, and individual funding request as it is expensive.
The growth factors and anti-inflammatory mediators in serum are also present in whole blood; which can be obtained using a finger prick technique as in diabetics, thus bypassing the cost and storage problems associated with autologous serum.
Finger prick autologous blood (FAB) has shown efficacy and safety in the treatment of severe dry eye syndrome patients and persistent corneal epithelial defects. In this study, the investigators aim to find out whether FAB is an effective alternative to long-term anti-inflammatories in the treatment of MGD. Patient's with MGD will be recruited from Moorfields Eye clinic at Bedford Hospital. The study will be conducted over 2 years.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients who have been diagnosed with meibomian gland dysfunction (based upon lid margin signs and consequent dry eye syndrome) with discomfort which affects their daily life, and who want further treatment and remain symptomatic despite optimum treatment (lid hygiene and massage, tried or are on artificial lubricants at least four times a day and tried or are on oral omega-3 oils).
Exclusion Criteria:
- Patients who do not have capacity to consent • Children (under 18 years old)
- Infected finger or systemic infection or on systemic antibiotics for infection
- Patients with immunodeficiency
- Infected finger or systemic infection or on systemic antibiotics for infection.
- Patients with active microbial infection, acute herpes simplex or herpes zoster keratitis, drug toxicity, vitamin A deficiency, or recurrent corneal erosion.
- Past Ophthalmic history of corneal transplantation.
- Pregnant or breast feeding women
- Fear of needles and unwillingness to carry out repeated finger pricks
- Past or current ocular malignancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Fingerprick Autologous Blood (FAB)
Assigned treatment with FAB
|
Pricking of cleaned finger using diabetic lancet and applying blood droplet to affected eye.
Repeated with separate finger for other affected eye.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement in clinical symptoms assessed using the OSDI questionnaire
Time Frame: 2 months
|
Ocular surface disease index questionnaire (OSDI)
|
2 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement of Meibomian Gland Dysfunction signs assessed using the International Workshop on Meibomian Gland Dysfunction report on grading criteria
Time Frame: 2 months
|
To improve signs (grading of MGD) as per 'The International Workshop on Meibomian Gland Dysfunction' report on grading criteria (Tomlinson, 2011)
|
2 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 473/2016/301
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Meibomian Gland Dysfunction
-
Hovione Scientia LimitedCompletedMeibomian Gland Dysfunction | MGD-Meibomian Gland DysfunctionUnited States
-
University of WaterlooCompletedMeibomian Gland Dysfunction (MGD)Canada
-
Second Affiliated Hospital, School of Medicine,...Aier Eye Hospital, WuhanCompletedMGD-Meibomian Gland DysfunctionChina
-
Barzilai Medical CenterCompletedMGD-Meibomian Gland DysfunctionIsrael
-
Singapore National Eye CentreNational University, SingaporeCompleted
-
Aier School of Ophthalmology, Central South UniversityUnknownMeibomian Gland Massage is Important to Delay the Development of Meibomian Gland DysfunctionChina
-
Johnson & Johnson Surgical Vision, Inc.CompletedCataracts | Meibomian Gland Dysfunction (MGD)United States
-
Azura OphthalmicsThe University of New South WalesCompletedMeibomian Gland Dysfunction (MGD) | Contact Lens Discomfort (CLD)Australia
-
Zhongnan HospitalRecruitingDry Eye | MGD-Meibomian Gland DysfunctionChina
-
Zhongnan HospitalRecruitingDry Eye | Positron-Emission Tomography | MGD-Meibomian Gland DysfunctionChina
Clinical Trials on Fingerprick autologous blood (FAB)
-
Bedford Hospital NHS TrustAnglia Ruskin UniversityUnknownDry Eye Syndromes
-
Bedford Hospital NHS TrustUnknownXerostomia | Xerostomia Due to Radiotherapy | Xerostomia Due to Hyposecretion of Salivary Gland
-
Erasmus Medical CenterRecruiting
-
Philips Handheld DiagnosticsUnknown
-
Cairo UniversityRecruitingTemporomandibular Joint DislocationEgypt
-
Cesca Therapeutics, Inc.UnknownCritical Limb Ischemia (CLI)
-
Radboud University Medical CenterCompletedSARS-CoV-2 InfectionNetherlands
-
Haukeland University HospitalDentsply Sirona Implants and ConsumablesCompleted
-
Rush University Medical CenterRecruitingPrimary Spontaneous PneumothoraxUnited States
-
National University Hospital, SingaporeNational Medical Research Council (NMRC), SingaporeCompletedHypoxic Ischemic EncephalopathySingapore